H.U. Group Holdings, Inc.

4544

JP3822000000

Healthcare Facilities & Services

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-24 EDT			5-day change	1st Jan Change
2,472 ^JPY	-0.66%		-2.18%	-7.19%

05-10	H.U. Group Holdings, Inc. Announces Dividend for the Fiscal Year Ended March 31, 2024, Payable on May 28, 2024; Provides Dividend Guidance for the Second Quarter-End and Fiscal Year Ending March 31, 2025	CI
05-02	H.U. Group Cuts Forecasts for Fiscal Year Ended March 31	MT

H.U. Group Holdings, Inc. Announces Retirement of Masaya Watanabe as Reprensentative Executive Officer, Effective June 22, 2021

April 25, 2021 at 09:30 pm

H.U. Group Holdings, Inc. announced the retirement of Masaya Watanabe as Reprensentative Executive Officer. Date of change (retirement) is June 22, 2021.

Latest news about H.U. Group Holdings, Inc.

H.U. Group Holdings, Inc. Announces Dividend for the Fiscal Year Ended March 31, 2024, Payable on May 28, 2024; Provides Dividend Guidance for the Second Quarter-End and Fiscal Year Ending March 31, 2025	05-09	CI
H.U. Group Cuts Forecasts for Fiscal Year Ended March 31	05-01	MT
H.U. Group Holdings, Inc. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024	04-26	CI
H.U. Group Holdings, Inc. Announces Retirement of Atsuko Murakami as Executive Officer	04-26	CI
H.U. Group Holdings, Inc. Announces Retirement of Atsuko Murakami as Chief Financial Officer	04-26	CI
H.U Unit Fujirebio Diagnostics Partners Beckman Coulter in Neurodegenerative Diseases Field	03-13	MT
Fujirebio and Beckman Coulter Expand Partnership to Develop Patient-Friendly, Blood-Based Neurodegenerative Disease Diagnostics	03-12	CI
H.U. Group Holdings Inc. and Fujirebio Announces the Availability of the Lumipulse G pTau 217 Plasma Assay for the Fully Automated LUMIPULSE G Immunoassay Systems	12-22	CI
Japanese Shares Rebound After Inflation Data, BoJ Rate Outlook	12-22	MT
H.U. Group to Issue Stock Options to Directors, Employees	12-21	MT
H.U. Group to Grant Share Options to Staff	11-19	MT
H.U. Group Holdings, Inc. Revises Earnings Guidance for the Fiscal Year Ending March 31, 2024	11-09	CI
H.U. Group Holdings, Inc.(TSE:4544) dropped from FTSE All-World Index	23-09-18	CI
H.U. Group Holdings' Fiscal Full-Year Profit Falls 47%	23-05-17	MT
H.U. Group Holdings, Inc. Announces Dividend for the Year Ended March 31, 2023, Payable on May 30, 2023; Provides Dividend Guidance for the Second Quarter and Full Year Ending March 31, 2024	23-05-16	CI
H.U. Group Holdings, Inc. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024	23-05-16	CI
H.U. Group Holdings, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-12	CI
H.U. Group Holdings, Inc. Announces Launch of the Fully Automated Lumipulse® G NfL CSF and Lumipulse® G NfL Blood tests	23-03-28	CI
H.U. Group Holdings, Inc. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2023	23-02-10	CI
H.U. Group Holdings, Inc. Provides Year End Dividend Forecast for the Fiscal Year Ending March 31, 2023	23-02-10	CI
H.U. Group Holdings, Inc. Provides Dividend Guidance for the Second Quarter-End and for the Full Year of Fiscal Year Ending March 31, 2023	22-08-15	CI
H.U. Group Holdings, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023	22-08-15	CI
Japan Equities End Week Higher; W-Scope Zooms 12% on Securing Approval for Unit's Listing in Korea	22-06-24	MT
H.U. Group Unit to Acquire Biomarker Assays Developer for $42 million	22-06-24	MT
H.U. Group Holdings, Inc. Provides Dividend Guidance for the Fiscal Year Ended March 31, 2022	22-05-20	CI

Chart H.U. Group Holdings, Inc.

Duration

Period

More charts

H.U. Group Holdings Inc, formerly Miraca Holdings Inc is a Japan-based holding company engaged in manufacture and sale of clinical test drugs, entrusted clinical examination and sterilization related business. The Company operates in four business segments. The Outsourced Clinical Testing segment accepts special tests from medical institutions. The Clinical Laboratory Medicine segment manufactures and sells clinical laboratory medicines and sells them to medical institutions and contract clinical laboratory companies. The Sterilization segment mainly entrusts the sterilization of medical equipment used for medical treatment in hospitals of large-scale hospitals and the related operations. The New Development & Others segment is involved in the homecare & welfare equipment business, self-medication & health insurance business, food & environment & cosmetics inspection business.

Sector

Healthcare Facilities & Services

Calendar

2024-08-05 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for H.U. Group Holdings, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2,472 JPY

Average target price

2,528 JPY

Spread / Average Target

+2.25%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
H.U. GROUP HOLDINGS, INC.	-7.19%	895M
SONIC HEALTHCARE LIMITED	-23.07%	7.86B
RADNET, INC.	+68.36%	4.32B
DR. LAL PATHLABS LIMITED	+1.88%	2.63B
SYNLAB AG	-8.06%	2.5B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-41.95%	2.33B
NEOGENOMICS, INC.	-11.99%	1.82B
FLEURY S.A.	-21.18%	1.51B
METROPOLIS HEALTHCARE LIMITED	+17.44%	1.22B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-43.89%	1.14B

Medical & Diagnostic Laboratories